Market Overview - The US market is experiencing significant news with the Federal Reserve being served a subpoena by Donald Trump's Department of Justice, which is perceived as a threat of criminal indictment against Jerome Powell [2][3] - This situation is expected to influence market commentary and trading, particularly affecting gold prices and NASDAQ futures [3] Company Performances - Imricor Medical Systems saw a substantial increase of nearly +20% after receiving FDA approval for its heart catheter device designed for MRI machines [4] - Light & Wonder's stock rose following the resolution of a dispute with Aristocrat Leisure over IP theft, resulting in a payment of nearly $200 million [5] - GreenX Metals' shares increased to $1 as it anticipates a payment of nearly $400 million from the Polish government in a long-running dispute [5] Declining Stocks - 4D Medical's shares are declining after a rapid increase in previous weeks, trading around $4.30 [5] - Mesoblast's stock is down approximately -5% despite posting record US revenues last week [6] - Super Retail Group's shares fell over -5% following a trading update that did not meet investor expectations [6]

Market Overview - Major U.S. index futures indicate a slightly lower open, with stocks likely to see further downside after three consecutive days of modest declines [1] - The tech-heavy Nasdaq is up by 21% for 2025, S&P 500 is up by 17%, and Dow is up by 13% [2] - Trading activity is subdued as traders prepare for New Year's Eve celebrations [2] Trading Activity - On Tuesday, major averages showed a lack of direction, ending modestly lower: Dow down 94.87 points (0.2%) to 48,367.06, Nasdaq down 55.27 points (0.2%) to 23,419.08, and S&P 500 down 9.50 points (0.1%) to 6,896.24 [3] - Biotechnology stocks fell significantly, with the NYSE Arca Biotechnology Index down by 1.5% [6] - Telecom stocks showed strength, driving the NYSE Arca North American Telecom Index up by 1.1% [7] Federal Reserve Insights - Traders were initially hesitant to make significant moves ahead of the Federal Reserve's monetary policy meeting minutes [4] - The minutes revealed mixed views on the outlook for interest rates, with some participants suggesting further rate cuts if inflation declines, while others felt rates should remain unchanged for some time [5] Commodity and Currency Markets - Crude oil futures increased by $0.57 to $58.52 per barrel after a previous decline [8] - Gold is trading at $4,339.30, down $47 from the previous session [8] - The U.S. dollar is trading at 156.76 yen, up from 156.39 yen [8] Asian Market Performance - Major Asian stock markets closed mixed, with Japan and South Korea markets closed [9] - China's Shanghai Composite Index edged up 0.1% to 3,968.84, while the Shenzhen Component Index fell by 0.6% [10] - The Hang Seng Index in Hong Kong slid 0.9% to 25,606.37 [11] European Market Performance - European stocks moved modestly lower, with the French CAC 40 Index down by 0.2% and the U.K.'s FTSE 100 Index down by 0.1% [14] - Notable declines included Stellantis down 1.7% and several other companies losing between 0.8% to 1.2% [15] U.S. Economic News - First-time claims for U.S. unemployment benefits unexpectedly dipped to 199,000, a decrease of 16,000 from the previous week [17][18] - The four-week moving average inched up to 218,750, an increase of 1,750 from the previous week's revised average [18]

Market Overview - Major U.S. index futures indicate a lower open on Monday, with stocks expected to give back gains after a strong performance last week [1] - Profit taking may contribute to initial weakness as traders look to cash in on recent gains ahead of the year-end [1] - The Dow and S&P 500 reached record closing highs last Thursday before slightly declining on Friday [1] Tech Sector Performance - A pullback in big-name tech companies, including Oracle, which is down over 2 percent in pre-market trading, may weigh on the market [2] - Nvidia and Micron Technology also show notable pre-market weakness after strong gains last week [2] Trading Activity - Stocks showed a lack of direction on Friday, with major averages bouncing around the unchanged line before closing slightly lower [3] - The S&P 500 reached a new record intraday high before closing down 2.11 points, or less than 0.1 percent, at 6,929.94 [3] Weekly Performance - Despite choppy trading, major averages posted strong weekly gains: S&P 500 up 1.4 percent, Dow and Nasdaq both up 1.2 percent [4] Sector Movements - Gold stocks showed significant strength, with the NYSE Arca Gold Bugs Index climbing 1.4 percent to a new record closing high [6] - Steel stocks also performed well, while airline and telecom stocks experienced moderate declines [6] Commodity and Currency Markets - Crude oil futures surged $1.41 to $58.15 a barrel after a previous drop [7] - Gold futures fell $84.30 to $4,460.40 an ounce after a significant increase in the prior session [7] - The U.S. dollar is trading at 156.26 yen, down from 156.54 yen, and at $1.1767 against the euro, slightly down from $1.1771 [7] Asian Market Performance - Asian stock markets displayed mixed performance amid weak sentiment from Wall Street futures and rising geopolitical tensions [8] - China's Shanghai Composite Index edged higher, recording a nine-session winning streak [9] European Market Performance - European stocks fluctuated between gains and losses amid cautious trading, with defense stocks declining due to progress in Ukraine peace talks [15] - The German DAX Index fell by 0.1 percent, while the U.K.'s FTSE 100 Index and the French CAC 40 Index rose by 0.1 percent and 0.2 percent, respectively [15] Economic Indicators - The National Association of Realtors is set to release a report on pending home sales, expected to increase by 0.8 percent in November [20] - The Energy Information Administration will report on crude oil inventories, anticipated to decrease by 2.6 million barrels [21]

Market Performance - Asian stock markets exhibited mixed performance, influenced by weak sentiment in Wall Street Futures and rising geopolitical tensions [1] - The Shanghai Composite Index increased by 2 points or 0.04% to close at 3,965.28, marking a nine-session winning streak [2] - The Japanese Nikkei 225 index decreased by 256 points or 0.51% to finish at 50,494.00 [2] - The Korean Kospi Index rose by 91 points or 2.2% to close at 4,220.56 [4] - The Hang Seng Index in Hong Kong fell by 184 points or 0.71% to end at 25,635.23 [4] - Australia's S&P/ASX200 index dropped by 37 points or 0.42% to close at 8,725.70 [5] - The NZX 50 in New Zealand decreased by 3 points or 0.02% to finish at 13,525.99 [7] Company Performance - Itochu Corp saw a significant increase of 5.3%, while Sumitomo Metal Mining and Fujikura both gained nearly 4% [3] - South32, Block, and Zip all rallied more than 2% [6] - Netwealth Group experienced a decline of 6.4%, followed by DroneShield with a 4.9% drop [6] - Pacific Edge led gains in New Zealand with a surge of 5.3% [7] - Investore Property topped losses with a decline of 1.7% [8] Geopolitical and Economic Factors - Geopolitical concerns regarding China, the Middle East, and Eastern Europe, along with thin trading ahead of New Year holidays, limited market gains [1]

Market Overview - Asian markets experienced weak sentiment as they reacted to the Federal Reserve's anticipated rate cut and forward guidance for 2026, with limited losses due to less hawkish guidance than expected [1] - The Shanghai Composite Index fell by 27 points or 0.70 percent, closing at 3,873.32, with a trading range between 3,862.82 and 3,904.96 [2] - The Japanese Nikkei 225 index decreased by 464 points or 0.92 percent, finishing at 50,139.00, with a trading range of 49,932.5 to 50,864 [2] - The Korean Kospi Index dropped by 24 points or 0.59 percent, closing at 4,110.62, with a trading range of 4,103.20 to 4,170.77 [4] - The Hang Seng Index in Hong Kong edged down by 10 points or 0.04 percent, closing at 25,530.51, with a trading range of 25,471.50 to 25,801.34 [4] Company Performance - Mitsui saw a significant increase of 4.85 percent, while Panasonic Corp and Advantest Corp both gained over 4.4 percent [3] - Toppan Printing rose by 3.2 percent, and Chugai Pharmaceutical increased by 2.8 percent [3] - SoftBank Group Corp led the losses with a decline of 7.7 percent, followed by Sumitomo Dainippon Pharma at 6.2 percent [3] - Catalyst Metals experienced the largest loss, declining by 8.9 percent, while Aerospace DroneShield fell by 6.6 percent [6] - James Hardie Industries topped gains in Australia with a surge of 7.1 percent, followed by Ramelius Resources at 6.7 percent [5] - The NZX 50 in New Zealand added 25 points or 0.19 percent, closing at 13,395.87, with a trading range of 13,355.70 to 13,433.41 [6]

Group 1 - Fintech company Findi is facing legal issues after a user claimed misconduct on forums, prompting the company's legal team to get involved [2] - PainChek's app for aged care homes received FDA approval, leading to increased attention as the company now focuses on sales [3] - Mesoblast's stock is gaining traction again as its stem cell drug Ryoncil shows sales momentum in the USA [4] Group 2 - Race Oncology's stock reached an all-time high after revealing the mechanism of action for its drug Bisantrene, which is believed to be a chemotherapy drug without side effects [4] - Trigg Minerals is exploring options for a NASDAQ listing, including a potential SPAC listing, as it targets the US critical metals market [5] - Fintech Stakk remains popular after securing deals with Robinhood and T-Mobile, alongside a $15 million placement currently under review [6]

Financial Data and Key Metrics Changes - Revenue from cell therapy products increased to $17.2 million, up 191% from the prior year, driven by the successful launch of Ryoncil [12][15] - Net operating cash spend for the year was $50 million, consistent with the prior year, despite investments in commercial team build-out and product launch activities [13][15] - Cash on hand as of June 30 was $162 million [13] Business Line Data and Key Metrics Changes - Ryoncil generated $13.2 million in gross sales and $11.3 million in net sales after a 14.6% gross to net adjustment [12] - Cost of revenues related to product sales was $1.2 million, representing 10% of net product sales, resulting in a gross margin of 90% [15] - Selling, general, and administrative expenses rose to $39.3 million, an increase of $14.3 million from FY 2024, primarily due to the commercial team build-out [15] Market Data and Key Metrics Changes - The addressable market for Ryoncil in pediatric acute graft versus host disease (GVHD) is significant, with potential label extensions in adult populations and other inflammatory diseases [9][10] - The addressable market for heart failure with reduced ejection fraction and chronic low back pain is estimated to exceed $10 billion each [9] Company Strategy and Development Direction - The company aims to expand Ryoncil's label to include adult patients with GVHD and other inflammatory conditions, leveraging existing pediatric treatment centers [24][25] - Plans to initiate pivotal studies for Ryoncil in inflammatory bowel disease and chronic low back pain are underway, targeting significant unmet medical needs [41][42] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the commercial launch of Ryoncil and its potential to transform the company from an R&D-focused entity to a commercial biotech organization [87] - The company is focused on building a robust commercial infrastructure to support ongoing sales growth and market access [76][82] Other Important Information - Ryoncil became commercially available on March 28, 2025, shortly after receiving FDA approval in December 2024 [10] - The company has onboarded 32 transplant centers in the U.S. and aims to reach 45 centers that account for 80% of pediatric bone marrow transplants [10][11] Q&A Session Summary Question: Timeline for adult GVHD label extension - Management expects to commence an adult acute GVHD trial this quarter, working with the NIH-funded Bone Marrow Transplant Clinical Trials Network [46][48] Question: Progress on Phase III chronic lower back pain trial - Enrollment is ongoing with nearly 40 sites, and management is optimistic about achieving similar outcomes as in previous trials [50][51] Question: Monthly treatment kits administered and inventory dynamics - Treatment kits are stocked based on weight bands, with replenishment occurring as children are treated [56][57] Question: Gross to net dynamics and adult GVHD trial design - Management expects gross to net adjustments to remain flat and plans to include patients on Jakafi in the adult trial to maximize market potential [59][60] Question: Details on adult study and trial design - The FDA is aligned with the company on trial design, focusing on early intervention in severe adult populations [64][66] Question: Timeline for inflammatory bowel disease trials - A KOL group is designing the trial, with plans to use both local and intravenous delivery methods [68] Question: Market access progress - The company has engaged with over 97 payers, achieving coverage for over 250 million lives, with Medicaid coverage in place across all states [82][83]

ASXNSB Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs August 2025 TechKnow Invest Roadshow Nathan Smith – Chief Executive Officer 1 For personal use only Disclaimers For personal use only Presentation Information This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information nece ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [6]. Core Insights - The report emphasizes the significant progress in stem cell therapy across multiple indications, suggesting a focus on companies like Jiuzhitang and Zhongyuan Qihe [3][5]. - The investment strategy is centered around three main themes: innovation, recovery, and policy support, with a strong emphasis on innovative drugs as the most clear long-term trend in the pharmaceutical sector [5]. Summary by Sections 1. Investment Focus on Pharmaceutical Combinations - The recommended investment combination outperformed the pharmaceutical index by 2.8 percentage points and the broader market by 3.1 percentage points last week [12]. 2. Stem Cell Therapy: Policy and Progress - China's regenerative medicine has reached a world-leading level, with clear industry policies marking a golden development period for stem cell therapy [17]. - Multiple indications are seeing critical advancements, with expectations for key data releases this year [17]. - The first domestically approved stem cell therapy was launched in January 2025, marking a historic turning point for the industry [6][17]. 3. Weekly Market Review and Hotspot Tracking (May 12-16, 2025) - The CITIC Pharmaceutical Index rose by 1.4%, outperforming the CSI 300 Index by 0.3 percentage points, ranking 10th among CITIC's primary industry classifications [61]. - The pharmaceutical sub-sectors showed positive performance, with chemical raw materials up by 2.79% and traditional Chinese medicine up by 2.01% [64].